DFTX Definium Therapeutics, Inc.

P/E --
Forward P/E --
Price/Sales --
Beta 2.258
Div Yield --
Market Cap --

Company Analysis

Latest News

πŸ”΄ DFTX is trading 6.9% down today on a $500M equity offering following Phase 3 data surge

DFTX is trading 6.9% down at $34.11 in pre-market action, pulling back from yesterday's significant gains following the announcement of a ~$500 million equity...

🟒 DFTX surges 49.8% today on positive Phase 3 results, then drops in after-hours on $500M equity offering

DFTX surged 49.80% to close at $36.67 today after reporting positive topline results from its Phase 3 Emerge study of DT120 ODT in Major Depressive Disorder. β€’...

Definium Therapeutics plans $500 million share sale following stock rally

Definium Therapeutics plans $500 million share sale following stock rally

Definium Therapeutics announced a proposed $500 million public offering of common shares and pre-funded warrants on June 22, 2026. The biopharmaceutical...

Definium's Depression Drug Clears a Key Hurdle, but Can a Single-Dose LSD Therapy Justify a $4 Billion Valuation?

Definium's Depression Drug Clears a Key Hurdle, but Can a Single-Dose LSD Therapy Justify a $4 Billion Valuation?

Shares of Definium Therapeutics surged +52.6% to $37.35 after the company reported that its lead psychedelic-based treatment β€” a single-dose, orally dissolving...

🟒 Definium Therapeutics, Inc. is trading 52.6% up today after positive Phase 3 Emerge results for DT120 ODT

Definium Therapeutics, Inc. is trading at $37.35 (+52.57%) after announcing positive topline Phase 3 Emerge results for DT120 ODT in major depressive...

Reports Positive Phase 3 Emerge Study Data for Depression Treatment DT120 ODT

Reports Positive Phase 3 Emerge Study Data for Depression Treatment DT120 ODT

Definium Therapeutics announced positive topline results from its Phase 3 Emerge study for DT120 ODT (lysergide), a treatment for adults with major depressive...

🟒 Definium Therapeutics, Inc. trading 13.4% up as company discusses Phase 3 Emerge study results today

Definium Therapeutics, Inc. is trading 13.4% up at $27.75 in pre-market. The company is discussing topline results from its Phase 3 Emerge study in Major...

πŸ”΄ Definium Therapeutics, Inc. is trading 4.4% down today as shares pull back after a multi-day run-up

Definium Therapeutics, Inc. is trading at $23.66 (4.4% down) as shares pull back following a multi-day run-up last week. β€’ No fresh company-specific news,...

🟒 Definium Therapeutics, Inc. extends move to 5.6% up

DFTX is trading at $24.55, up 5.6% versus the comparison close of $23.24 during regular trading. This is a price-movement alert; no separate company-specific...

🟒 Definium Therapeutics, Inc. is trading 4.7% up today following institutional accumulation and sector momentum

Definium Therapeutics, Inc. is trading 4.7% up at $24.34, extending a multi-day rebound as the stock benefits from institutional accumulation and a broader...

🟒 Definium Therapeutics, Inc. is trading 4.8% up today amid broader biotech volatility and market sentiment

Definium Therapeutics, Inc. is trading at $24.05 (+4.79%) today, with the move appearing tied to broader market sentiment rather than a specific company...

🟒 Definium Therapeutics, Inc. is trading 5.71% up

DFTX is trading at $24.26, up 5.71%.

πŸ”΄ Definium Therapeutics, Inc. is trading 5.2% down today on broader risk-off sentiment ahead of U.S. CPI data

Definium Therapeutics, Inc. is trading 5.2% down at $21.75 in pre-market as broader risk-off sentiment pressures growth and therapeutics names ahead of key...

πŸ”΄ Definium Therapeutics, Inc. is trading 5.2% down today as rate fears and macro volatility weigh on growth stocks

Definium Therapeutics, Inc. is trading 5.2% down at $21.82 as the stock extends a multi-day pullback amid broader market weakness and higher-for-longer...

πŸ”΄ Definium Therapeutics, Inc. is trading 4.3% down today as macro worries extend multi-day pullback

Definium Therapeutics, Inc. is trading 4.3% down today at $22.02 as the stock extends a multi-day pullback amid broader macro and interest rate concerns. β€’...

πŸ”΄ Definium Therapeutics, Inc. is trading 5.6% down today on continued profit-taking and macro concerns

Definium Therapeutics, Inc. is trading 5.6% down at $22.23 as the stock undergoes a sharp two-day pullback following last week’s run-up and Friday’s...

πŸ”΄ Definium Therapeutics, Inc. is trading 5.1% down today as hot jobs data fuels interest rate concerns

Definium Therapeutics, Inc. is trading 5.1% down at $23.34 after a hotter-than-expected U.S. jobs report pushed interest rate expectations higher and pressured...

πŸ”΄ Definium Therapeutics, Inc. is trading 4.1% down today as strong U.S. jobs data fuels rate concerns

Definium Therapeutics, Inc. is trading 4.1% down at $23.58 today as a stronger-than-expected U.S. jobs report and rising interest rate expectations weigh on...

🟒 Definium Therapeutics, Inc. up 5% as investors anticipate key Phase 3 data

Definium Therapeutics, Inc. is trading at $24.78 (+5.04%) as investor anticipation builds ahead of key clinical trial results and following a positive...

πŸ”΄ Definium Therapeutics, Inc. is trading 6% down today as selling pressure persists following its Q1 2026 earnings miss

Definium Therapeutics, Inc. is trading 6% down at $22.61 as selling pressure persists following its recent Q1 2026 earnings miss and soft investor reaction. β€’...